X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM. It is under phase 1 clinical development for the treatment of non-small cell lung cancer, melanoma or renal cell carcinoma.
Lead Product(s): BMC128,Nivolumab
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
The proceeds will be used to complete Biomica's current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial and to scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of IBD.
Lead Product(s): BMC128,Nivolumab
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Healthcare Capital
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2023
Details:
BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene's MicroBoost AI platform.
Lead Product(s): BMC128,Nivolumab
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform.
Lead Product(s): BMC128,Nivolumab
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Biomica’s abstract entitled “A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors”, was selected for a poster and presentation session at the conference which showcase the potential of BMC128.
Lead Product(s): BMC128,Undisclosed
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The clinical trial agreement (CTA) is signed for initiating a first in-human proof-of-concept (POC) for BMC128, Biomica's drug candidate which is rationally-designed LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract.
Lead Product(s): BMC128,Immune Checkpoint Inhibitor Immunotherapy
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rambam Health Care Campus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2021
Details:
BMC128 is advancing to the GMP production stage following the successful completion of the initial R&D stage of drug product development and manufacturing, conducted by Biose Industrie (Aurillac, France).
Lead Product(s): BMC128,Immune checkpoint inhibitor
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Biomica’s current results demonstrate that treatment with BMC128 prior to and in combination with the administration of ICI, significantly reduced tumor volume and increased animal survival compared to ICI therapy alone.
Lead Product(s): BMC128,Immune checkpoint inhibitor
Therapeutic Area: Oncology Product Name: BMC128
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
